Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:5 Issue:9 Number:39 ISSN#:2564-2537
ACE Report #9096
Ace Report Cover Metabolic Disorders

Comparison of risedronate, alendronate, zoledronate, and ibandronate in those with low BMD

How to Cite

OrthoEvidence. Comparison of risedronate, alendronate, zoledronate, and ibandronate in those with low BMD. ACE Report. 2016;5(9):39. Available from: https://myorthoevidence.com/AceReport/Report/9096

Study Type:Meta analysis
OE Level Evidence:2
Journal Level of Evidence:N/A

Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis

Bone. 2016 Aug;89:52-8

Contributing Authors: J Sanderson M Martyn-St James J Stevens E Goka R Wong F Campbell P Selby N Gittoes S Davis

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


A total of 27 randomized controlled trials were included in this network meta-analysis investigating the comparative efficacies of bisphosphonates - including alendronate, ibandronate, risedronate, and zoledronic acid - versus placebo or control in patients with low bone mineral density. All studied drugs demonstrated significant effects on vertebral fracture incidence and bone mineral density of ...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.